Search our Innovation Portfolio

By 2020 one in two people in the UK will be diagnosed with Cancer at some point in their life. Approximately 50% will be diagnosed late, with an associated 80% mortality. Our innovation, C the Signs, is a digital tool (App & website) that uses the latest evidence to help GPs identify patients with suspected Cancer early. Covering the entire spectrum of Cancer and cross-referencing multiple diagnostic pathways, C the Signs can support GPs in recommending what tests, investigations or referrals a patient may need in under 30 seconds.

Aidence provides Artificial Intelligence (AI) solutions for analyses of medical images and data. Lung CAD (L-CAD) is the company’s first CE-certified software providing highly accurate detection and reporting of pulmonary nodules on CT-chest. Initially, L-CAD supports radiologists as a second reader, enabling shorter reading times and improving diagnostic accuracy.

However, we propose to develop L-CAD as first reader, reducing the radiology burden by autonomously reporting follow up studies or even acting as a filter to remove unsuspicious studies from the workflow. L-CAD is an enabler of a safe and efficient lung screening program.

Cambridge Oncometrix is developing a non-invasive Prostate Liquid Biopsy test for risk stratification of men suspected of prostate cancer. The test measures the chemical element profile of semen, which changes significantly when a tumour is present in the prostate.

Prostate Liquid Biopsy is non-invasive and simple to administer, and will improve treatment outcomes by diagnosing prostate cancer earlier. The test will aid identification of men who will benefit from prostate biopsy and those who could safely forgo it, which will reduce the number of invasive biopsy procedures and post-biopsy complications, improve patients’ experience and aid efficient use of NHS resources.